Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program
Executive Summary
Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.